Home Companies Catalysts Deep Dives
Tivdak tisotumab vedotin APPROVED
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Launch2021-09-20
US LOE2033-09-20
Peak Sales Est$1000M
Formulations[{"id":"tivdak-iv","route":"IV","setting":"INFUSION_CENTER","frequency":"Every 3 weeks","is_primary"
Companies
GMAB (CO_DEVELOPER)50%
PFE (CO_DEVELOPER)50%
Mechanism: Tissue factor-targeting ADC
Expert: Antibody-drug conjugate targeting tissue factor with MMAE payload for cervical and other solid tumors.
Everyday: A targeted drug that delivers chemotherapy to cancer cells expressing tissue factor.
Targets: ["TF"]
Revenue History
PeriodRevenue ($M)
2024$280M
2025$400M
Programs (1)
IndicationStageKey StudyRegional Status
R/R CervCaAPPROVEDinnovaTV 301[{"stage":"APPROVED","region":"US","approval_date":"2024-04-29"},{"stage":"APPRO
Notes
First tissue factor-targeting ADC for cervical cancer. Confirmed approval 2024. Now launching in EU (Germany first). Co-developed with Pfizer (Seagen).
Data from Supabase · Updated 2026-03-24